Inhibition of in vivo tumour growth by the blocking of host αvβ3 and αIIbβ 3 integrins

Anticancer Research

Volumn 29, Issue 1, 2009, Pages 131-137

  Engebraaten, Olav ^a,c   Trikha, Mohit ^b   Juell, Siri ^a   Garman Vik, Solveig ^a   Fodstad, Øystein ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b CENTOCOR INC   (United States)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Angiogenesis; Animal model; Experimental therapy; Integrin; Metastasis

Indexed keywords

ALPHA2B BETA3 INTEGRIN; BASIC FIBROBLAST GROWTH FACTOR; IMMUNOGLOBULIN F(AB')2 FRAGMENT; INTEGRIN; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN FRAGMENT;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER INVASION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; NONHUMAN; NUDE RAT; PRIORITY JOURNAL; RAT; TIBIA; TUMOR GROWTH; ANIMAL; BIOSYNTHESIS; BREAST TUMOR; CELL GROWTH; DRUG ANTAGONISM; DRUG SCREENING; FLOW CYTOMETRY; HELA CELL; IMMUNOLOGY; METABOLISM; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; HELA CELLS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; INTEGRIN ALPHAVBETA3; MALE; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RATS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 61449094944     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Brower V: Tumor angiogenesis - new drugs on the block. Nat Biotechnol 17(10): 963-968, 1999.
2. Eder JP Jr, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, Shulman LN, Proper J, Kirvan M, Rattner B, Connors S, Keogan MT, Janicek MJ, Fogler WE, Schnipper L, Kinchla N, Sidor C, Phillips E, Folkman J and Kufe DW: Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 20(18): 3772-3784, 2002.
3. Miller KD: Recent translational research: antiangiogenic therapy for breast cancer - where do we stand? Breast Cancer Res 6(3): 128-132, 2004.
4. Jain RK, Duda DG, Clark JW and Loeffler JS: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3(1): 24-40, 2006.
5. Poon RT, Fan ST and Wong J: Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 19(4): 1207-1225, 2001.
6. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D and Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26): 2666-2676, 2007.
7. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23): 2335-2342, 2004.
8. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79: 1157-1164, 1994.
9. Varner JA, Nakada MT, Jordan RE and Coller BS: Inhibition of angiogenesis and tumor growth by murine 7E3, the parent antibody of c7E3 Fab (abciximab; ReoPro). Angiogenesis 3(1): 53-60, 1999.
10. Mitjans F, Meyer T, Fittschen C, Goodman S, Jonczyk A, Marshall JF, Reyes G and Piulats J: In vivo therapy of malignant melanoma by means of antagonists of alpha v integrins. Int J Cancer 87(5): 716-723, 2000.
11. Petitclerc E, Stromblad S, von Schalscha TL, Mitjans F, Piulats J, Montgomery AM, Cheresh DA and Brooks PC: Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res 59(11): 2724-2730, 1999.
12. Berry MG, Gui GP, Wells CA and Carpenter R: Integrin expression and survival in human breast cancer. Eur J Surg Oncol 30(5): 484-489, 2004.
13. Furger KA, Allan AL, Wilson SM, Hota C, Vantyghem SA, Postenka CO, Al-Katib W, Chambers AF and Tuck AB: Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Mol Cancer Res 1(11): 810-819, 2003.
14. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH and Cheresh DA: Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96(4): 1815-1822, 1995.
15. Nakada MT, Cao G, Sassoli PM and DeLisser HM: c7E3 Fab inhibits human tumor angiogenesis in a SCID mouse human skin xenograft model. Angiogenesis 9(4): 171-176, 2006.
16. 3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases. Clin Exp Metastasis 20: 413-420, 2003.
17. Engebraaten O and Fodstad O: Site-specific experimental metastasis patterns of two human breast cancer cell lines in nude rats. Int J Cancer 82(2): 219-225, 1999.
18. Naundorf H, Rewasowa EC, Fichtner I, Buttner B, Becker M and Gorlich M: Characterization of two human mammary carcinomas, MT-1 and MT-3, suitable for in vivo testing of ether lipids and their derivatives. Breast Cancer Res Treat 23(1-2): 87-95, 1992.
19. MacLeod RA, Dirks WG, Matsuo Y, Kaufmann M, Milch H and Drexler HG: Widespread intraspecies cross-contamination of human tumor cell lines arising at source. Int J Cancer 83(4): 555-563, 1999.
20. Rye PD, Norum L, Olsen DR, Garman-Vik S, Kaul S and Fodstad Ø: Brain metastasis model in athymic nude mice using a novel MUC1-secreting human breast-cancer cell line, MA11. Int J Cancer 68(5): 682-687, 1996.
21. Kjønniksen I, Winderen M, Bruland Ø and Fodstad Ø: Validity and usefulness of human tumor models established by intratibial cell inoculation in nude rats. Cancer Res 54: 1715-1719, 1994.
22. Kjønniksen I, Nesland JM, Pihl A and Fodstad Ø: Nude rat model for studying metastasis of human tumor cells to bone and bone marrow. J Natl Cancer Inst 82(5): 408-412, 1990.
23. Kerbel RS: Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 13(1): 31-36, 1991.
24. Eliceiri BP, Klemke R, Stromblad S and Cheresh DA: Integrin alpha (v) beta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol 140(5): 1255-1263, 1998.
25. Hood JD, Frausto R, Kiosses WB, Schwartz MA and Cheresh DA: Differential alpha (v) integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J Cell Biol 162(5): 933-943, 2003.
26. Soldi R, Mitola S, Strasly M, Defilippi P, Tarone G and Bussolino F: Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. Embo J 18(4): 882-892, 1999.
27. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M and Heldin CH: Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269(43): 26988-26995, 1994.
28. Trikha M, Zhou Z, Timar J, Raso E, Kennel M, Emmell E and Nakada MT: Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res 62(10): 2824-2833, 2002.
29. Eskens FA, Dumez H, Hoekstra R, Perschl A, Brindley C, Bottcher S, Wynendaele W, Drevs J, Verweij J and van Oosterom AT: Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 39(7): 917-926, 2003.
30. Tucker GC: Alpha v integrin inhibitors and cancer therapy. Curr Opin Investig Drugs 4(6): 722-731, 2003.
31. Posey JA, Khazaeli MB, DelGrosso A, Saleh MN, Lin CY, Huse W and LoBuglio AF: A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm 16(2): 125-132, 2001.
32. Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ and Cheresh DA: Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 6(8): 3056-3061, 2000.
33. Mullamitha SA, Ton NC, Parker GJ, Jackson A, Julyan PJ, Roberts C, Buonaccorsi GA, Watson Y, Davies K, Cheung S, Hope L, Valle JW, Radford JA, Lawrance J, Saunders MP, Munteanu MC, Nakada MT, Nemeth JA, Davis HM, Jiao Q, Prabhakar U, Lang Z, Corringham RE, Beckman RA and Jayson GC: Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res 13(7): 2128-2135, 2007.
34. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S and DeNardo GL: Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 62(15): 4263-4272, 2002.